The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy

Inti Zlobec, Te Vuong, Carolyn C. Compton

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy. METHODS. Immunohistochemistry for APAF-1 was performed on 94 rectal tumor biopsy specimens from patients who were treated on a preoperative, high-dose-rate brachytherapy protocol. Tumors were considered positive when > 10% of tumor cells were immunoreactive. The association between APAF-1 expression and tumor response was made using the chi-square test. RESULTS. Forty-four tumors (43%) were positive for APAF-1. Thirty tumors had complete pathologic tumor regression after preoperative radiotherapy. Of these, 18 tumors were positive for APAF-1. A partial response occurred in 35 tumors. Eighteen tumors (51%) were positive for the protein. Only 8 of 29 nonresponsive tumors (28%) were immunoreactive for APAF-1. A significant association was found between complete tumor regression and positive APAF-1 status (P = 0.018). APAF-1 expression in partially responsive tumors was significantly greater than in nonresponsive tumors (P = 0.03). CONCLUSIONS. APAF-1 expression in pretreatment rectal tumor biopsy specimens may be useful as a predictive marker of response to preoperative radiotherapy in patients with rectal carcinoma.

Original languageEnglish (US)
Pages (from-to)284-286
Number of pages3
JournalCancer
Volume106
Issue number2
DOIs
StatePublished - Jan 15 2006
Externally publishedYes

Fingerprint

Brachytherapy
Rectal Neoplasms
Peptide Hydrolases
Apoptosis
Neoplasms
Radiotherapy
Biopsy
Chi-Square Distribution
Immunohistochemistry

Keywords

  • Apoptosis protease-activating factor 1
  • Preoperative radiotherapy
  • Rectal carcinoma
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. / Zlobec, Inti; Vuong, Te; Compton, Carolyn C.

In: Cancer, Vol. 106, No. 2, 15.01.2006, p. 284-286.

Research output: Contribution to journalArticle

@article{e587ff3ccde64c0794ac0d47bae6c348,
title = "The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy",
abstract = "BACKGROUND. The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy. METHODS. Immunohistochemistry for APAF-1 was performed on 94 rectal tumor biopsy specimens from patients who were treated on a preoperative, high-dose-rate brachytherapy protocol. Tumors were considered positive when > 10{\%} of tumor cells were immunoreactive. The association between APAF-1 expression and tumor response was made using the chi-square test. RESULTS. Forty-four tumors (43{\%}) were positive for APAF-1. Thirty tumors had complete pathologic tumor regression after preoperative radiotherapy. Of these, 18 tumors were positive for APAF-1. A partial response occurred in 35 tumors. Eighteen tumors (51{\%}) were positive for the protein. Only 8 of 29 nonresponsive tumors (28{\%}) were immunoreactive for APAF-1. A significant association was found between complete tumor regression and positive APAF-1 status (P = 0.018). APAF-1 expression in partially responsive tumors was significantly greater than in nonresponsive tumors (P = 0.03). CONCLUSIONS. APAF-1 expression in pretreatment rectal tumor biopsy specimens may be useful as a predictive marker of response to preoperative radiotherapy in patients with rectal carcinoma.",
keywords = "Apoptosis protease-activating factor 1, Preoperative radiotherapy, Rectal carcinoma, Tumor marker",
author = "Inti Zlobec and Te Vuong and Compton, {Carolyn C.}",
year = "2006",
month = "1",
day = "15",
doi = "10.1002/cncr.21600",
language = "English (US)",
volume = "106",
pages = "284--286",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy

AU - Zlobec, Inti

AU - Vuong, Te

AU - Compton, Carolyn C.

PY - 2006/1/15

Y1 - 2006/1/15

N2 - BACKGROUND. The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy. METHODS. Immunohistochemistry for APAF-1 was performed on 94 rectal tumor biopsy specimens from patients who were treated on a preoperative, high-dose-rate brachytherapy protocol. Tumors were considered positive when > 10% of tumor cells were immunoreactive. The association between APAF-1 expression and tumor response was made using the chi-square test. RESULTS. Forty-four tumors (43%) were positive for APAF-1. Thirty tumors had complete pathologic tumor regression after preoperative radiotherapy. Of these, 18 tumors were positive for APAF-1. A partial response occurred in 35 tumors. Eighteen tumors (51%) were positive for the protein. Only 8 of 29 nonresponsive tumors (28%) were immunoreactive for APAF-1. A significant association was found between complete tumor regression and positive APAF-1 status (P = 0.018). APAF-1 expression in partially responsive tumors was significantly greater than in nonresponsive tumors (P = 0.03). CONCLUSIONS. APAF-1 expression in pretreatment rectal tumor biopsy specimens may be useful as a predictive marker of response to preoperative radiotherapy in patients with rectal carcinoma.

AB - BACKGROUND. The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy. METHODS. Immunohistochemistry for APAF-1 was performed on 94 rectal tumor biopsy specimens from patients who were treated on a preoperative, high-dose-rate brachytherapy protocol. Tumors were considered positive when > 10% of tumor cells were immunoreactive. The association between APAF-1 expression and tumor response was made using the chi-square test. RESULTS. Forty-four tumors (43%) were positive for APAF-1. Thirty tumors had complete pathologic tumor regression after preoperative radiotherapy. Of these, 18 tumors were positive for APAF-1. A partial response occurred in 35 tumors. Eighteen tumors (51%) were positive for the protein. Only 8 of 29 nonresponsive tumors (28%) were immunoreactive for APAF-1. A significant association was found between complete tumor regression and positive APAF-1 status (P = 0.018). APAF-1 expression in partially responsive tumors was significantly greater than in nonresponsive tumors (P = 0.03). CONCLUSIONS. APAF-1 expression in pretreatment rectal tumor biopsy specimens may be useful as a predictive marker of response to preoperative radiotherapy in patients with rectal carcinoma.

KW - Apoptosis protease-activating factor 1

KW - Preoperative radiotherapy

KW - Rectal carcinoma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=30744477459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744477459&partnerID=8YFLogxK

U2 - 10.1002/cncr.21600

DO - 10.1002/cncr.21600

M3 - Article

VL - 106

SP - 284

EP - 286

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -